The study conducted at Musashino Red Cross Hospital in Tokyo evaluated the effectiveness and safety of radiofrequency ablation (RFA) for treating hepatocellular carcinoma (HCC) in patients aged 80 years and older. The analysis included 518 patients, of which 136 were elderly (≥80 years) and 382 were younger (<80 years).
The study conducted at Musashino Red Cross Hospital in Tokyo evaluated the effectiveness and safety of radiofrequency ablation (RFA) for treating hepatocellular carcinoma (HCC) in patients aged 80 years and older. The analysis included 518 patients, of which 136 were elderly (≥80 years) and 382 were younger (<80 years). All patients had tumors ≤3 cm and ≤3 nodules within the Milan criteria.
Key findings for elderly patients (≥80 years) include:
1. **Overall Survival (OS)**: Median OS for elderly patients was 80 months, significantly shorter than the 123 months observed in younger patients (p=0.021). However, age itself did not significantly affect liver disease-related mortality.
2. **Recurrence-Free Survival (RFS)**: Median RFS was shorter for elderly patients (17 months) compared to younger patients (27 months), with a statistically significant difference (p=0.017). Elderly age was identified as a risk factor for recurrence.
3. **Prognostic Factors**: Poor survival and recurrence were associated with higher ALBI grade, elevated DCP levels (≥40 mAU/mL), persistent HCV infection, and nonviral liver disease.
4. **Safety and Complications**: RFA demonstrated acceptable safety with only 3.9% of patients experiencing complications (e.g., bleeding, pneumothorax, renal dysfunction), and no treatment-related deaths were reported.
5. **Clinical Implication**: Despite slightly shorter survival, RFA remains a viable, safe, and effective treatment for elderly HCC patients. Age ≥80 years did not significantly impact liver disease-specific mortality, indicating effective post-recurrence management.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.